Showing 4391-4400 of 7638 results for "".
- 'Sun Safe' Study: Children Seek Shade if Availablehttps://practicaldermatology.com/news/20140812-sun_safe_study_children_seek_shade_if_available/2459147/A new study by the founder of Sun Safe Soccer reveals nearly two-thirds of children will use shade tents during soccer breaks without any prompting from coaches. The study, published in JAMA Dermatology, was conducted by Ian Maher, M.D., who developed the Sun Safe Soccer skin cancer prevention pro…
- Editorial: Transferrable Loyalty and the State of Our Specialtyhttps://practicaldermatology.com/news/20140806-editorial_transferrable_loyalty_and_the_state_of_our_specialty/2459149/With the ongoing battle between Allergan and Valeant, it is evident that no practicing dermatologist can avoid concerns with the painful and tactical machinations. Long-term representatives have likely already changed their nametags from one company to another and are now pitching the same drugs un…
- FDA Warns of Adverse Events Associated with Unapproved Use of Expression Injectable as a Dermal Fillerhttps://practicaldermatology.com/news/20140806-fda_warns_of_adverse_events_associated_with_unapproved_use_of_expression_injectable_as_a_dermal_filler/2459150/The FDA reported that it has become aware of adverse events associated with the unapproved use of the Expression product, hyaluronic acid that is packaged in a syringe, as a dermal filler. Events have included swelling, tenderness, firmness, lumps, bumps, bruising, pain, redness, discoloration, itc…
- New Data Show High Efficacy for Can-Fite's CF101 in Rheumatoid Arthritis and Psoriasis Patientshttps://practicaldermatology.com/news/20140806-new_data_show_high_efficacy_for_can-fites_cf101_in_rheumatoid_arthritis_and_psoriasis_patients/2459151/New data from a retrospective analysis of its autoimmune disease advanced trials show high efficacy of Can-Fite BioPharma Ltd.'s orally bioavailable drug CF101. The retrospective study, conducted by a third-party statistician group, analyzed the correlation between response to CF101 and patients'…
- Cynosure's PicoSure Laser Cleared by FDA for Acne Scarshttps://practicaldermatology.com/news/20140801-cynosure_announces_picosure_is_fda-cleared_to_treat_acne_scars/2459153/The FDA cleared the PicoSure picosecond laser to treat acne scars. "We are thrilled to announce that PicoSure, the world's most advanced laser technology for tattoo removal and benign pigmented lesions, has now received FDA-clearance to treat acne scars," says Cynosure President and CEO Michael D…
- Cynosure Appoints Timothy W. Baker as Presidenthttps://practicaldermatology.com/news/20140730-cynosure_appoints_timothy_w_baker_as_president/2459154/The Board of Directors of Cynosure, Inc., which develops and markets laser- and light-based aesthetic treatments for non-invasive and minimally invasive applications, promoted Executive Vice President, Chief Operating Officer and Chief Financial Officer Timothy W. Baker to President of the Company,…
- FDA Approves of Acticlate Tablets from Aqua Pharmaceuticals, LLChttps://practicaldermatology.com/news/20140728-aqua_pharmaceuticals_llc_announces_fda_approval_of_acticlate_tablets/2459155/The FDA approved Aqua Pharmaceuticals' Acticlate (doxycycline hyclate USP) Tablets, 150 mg and 75 mg, an oral antibiotics for acne. Acticlate is a tetracycline-class antibacterial indicated for the treatment of a number of infections, including adjunctive therapy in severe acne. Acticlate, accordi…
- Psoriasis Foundation Awards 13 Research Fellowshipshttps://practicaldermatology.com/news/20140721-psoriasis_foundation_awards_13_research_fellowships/2459162/The National Psoriasis Foundation awarded 13 residents and medical students each a one-year, $50,000 fellowship to study psoriasis. The fellowships aim to increase the number of scientists studying and treating psoriatic disease by encouraging promising doctors to dedicate their careers to the stud…
- Anacor Pharmaceuticals and Sandoz Enter Into an Agreement for the Commercialization of Kerydin in the UShttps://practicaldermatology.com/news/20140721-anacor_pharmaceuticals_and_sandoz_enter_into_an_agreement_for_the_commercialization_of_kerydin_in_the_us/2459163/Anacor Pharmaceuticals, Inc. has entered into an exclusive agreement with Sandoz Inc., a Novartis company, pursuant to which Sandoz will distribute and commercialize Anacor's recently approved Kerydin (tavaborole) topical solution, 5% in the US. PharmaDerm, the branded dermatology business of Sando…
- LEO Pharma and KLOX Technologies Strike Global Dermatology Dealhttps://practicaldermatology.com/news/20140715-leo_pharma_and_klox_technologies_strike_global_dermatology_deal/2459167/LEO Pharma A/S and KLOX Technologies Inc. have entered into a worldwide license and joint venture agreement, excluding Canada, to further develop and commercialize KLOX's BioPhotonic technology platform in dermatology, which includes a CE-approved treatment for moderate to severe acne. LEO Pharma w…